Current opinion in anaesthesiology · 2026
Xenon anesthesia: shedding light on brain dynamics and clinical niches.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baima Tomás, Landoni Giovanni, Luedi Markus M, Romero Carolina S
Аннотация
PURPOSE OF REVIEW: Xenon is reemerging as a clinically attractive inhalational anesthetic because it combines rapid kinetics and cardiovascular stability with mechanism features that differ from GABAergic agents. Simultaneously, new membrane-biophysics and systems-neuroscience data are reshaping how models in anesthetic state transitions worked, which expands the future of how anesthetic agents are used.
RECENT FINDINGS: Contemporary work strengthens the view that xenon acts primarily via noncompetitive NMDA receptor inhibition, with additional effects on excitability-related ion channels. Whole-cortex modeling and high-density electroencephalogram studies link xenon sedation to reduced long-range coupling, slowed alpha peak frequency, increased damping of alpha-band dynamics, and a shift toward more stable population dynamics that track response better than gas concentration. Despite this, xenon's studies do not show a consistent reduction in postoperative neurocognitive disorders. However, xenon has been shown to accelerate early recovery anesthesia times.
SUMMARY: Though definitive outcome benefits remain unproven, xenon's value may represent a reemergent inhalational drug as the environmental carbon dioxide footprint is very attractive. Besides, the rapid recovery of xenon's general anesthesia, is also a distinct, quantifiable systems-level physiology that can guide depth monitoring and motivate targeted trials, improving the design and protocol of the studies in high-risk neurocognitive and brain-injury settings.
RECENT FINDINGS: Contemporary work strengthens the view that xenon acts primarily via noncompetitive NMDA receptor inhibition, with additional effects on excitability-related ion channels. Whole-cortex modeling and high-density electroencephalogram studies link xenon sedation to reduced long-range coupling, slowed alpha peak frequency, increased damping of alpha-band dynamics, and a shift toward more stable population dynamics that track response better than gas concentration. Despite this, xenon's studies do not show a consistent reduction in postoperative neurocognitive disorders. However, xenon has been shown to accelerate early recovery anesthesia times.
SUMMARY: Though definitive outcome benefits remain unproven, xenon's value may represent a reemergent inhalational drug as the environmental carbon dioxide footprint is very attractive. Besides, the rapid recovery of xenon's general anesthesia, is also a distinct, quantifiable systems-level physiology that can guide depth monitoring and motivate targeted trials, improving the design and protocol of the studies in high-risk neurocognitive and brain-injury settings.